We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04261855
Recruitment Status : Recruiting
First Posted : February 10, 2020
Last Update Posted : February 15, 2023
Information provided by (Responsible Party):
Melanoma and Skin Cancer Trials Limited

Brief Summary:
10.17 GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate the safety and anti-tumour activities of the novel combination of avelumab with 177-Lu-DOTATATE (a type of peptide receptor radionuclide therapy; PRRT) or external beam radiation therapy (EBRT) in patients with metastatic Merkel cell carcinoma (mMCC).

Condition or disease Intervention/treatment Phase
Metastatic Merkel Cell Carcinoma Drug: Avelumab Radiation: External Beam Radiation Therapy (EBRT) Radiation: Lutetium-177 (177Lu)-DOTATATE Phase 1 Phase 2

Detailed Description:

Despite recent advances with immune checkpoint inhibitors, such as avelumab which has changed the treatment landscape for metastatic Merkel Cell Carcinoma (mMCC), many mMCC patients who attained an initial response exhibit acquired resistance within 1 year. Therefore, novel treatment combinations are needed to improve patient outcome. MCC is an exquisitely radiosensitive tumour and there is emerging data supporting the role of radiation in inducing immunogenic cell death and therefore potentially improving the anti-tumour efficacy when combined with immune checkpoint inhibitors. Peptide receptor radionuclide therapy (PRRT) is used in first-line treatment for neuroendocrine tumours (NETs), by delivering radiation to somatostatin receptor (SSTR) expressing tumour cells. Most NETs, including MCC, express SSTR. Therefore, MCC tumours are ideal candidates for PRRT, and immune checkpoint inhibitor combination approaches with PRRT are highly attractive.

The GoTHAM trial is intended as a signal-seeking and biomarker study. It is designed as a prospective, open-labelled, multi-institutional, two-arm, phase Ib/II trial that will evaluate the safety and anti-tumour activity of 177Lu-DOTA-octreotate (LuTate) or external beam radiation therapy (EBRT) in combination with avelumab in patients with mMCC. The primary objective is to evaluate the anti-tumour activity as reflected by PFS rate at 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma
Actual Study Start Date : October 8, 2020
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : January 2024

Arm Intervention/treatment
Experimental: Arm A
Avelumab plus External Beam Radiation Therapy (EBRT)
Drug: Avelumab
All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
Other Names:
  • Bavencio
  • Anti-PD-L1

Radiation: External Beam Radiation Therapy (EBRT)
Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
Other Name: Radiotherapy

Experimental: Arm B
Avelumab plus Lutetium-177 (177Lu)-DOTATATE
Drug: Avelumab
All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
Other Names:
  • Bavencio
  • Anti-PD-L1

Radiation: Lutetium-177 (177Lu)-DOTATATE
Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart
Other Names:
  • Peptide Receptor Radionuclide Therapy (PRRT)
  • Lutathera

Primary Outcome Measures :
  1. Progression Free Survival (PFS) at 12 months [ Time Frame: 3 years ]
    To evaluate the anti-tumour activity as reflected by PFS rate at 12 months. PFS is defined as the time from treatment initiation until the first date of documented radiographic progression or death due to any cause, whichever occurs first. The radiographic progression will be assessed by the Investigator according to RECIST v1.1.

Secondary Outcome Measures :
  1. Progression Free Survival (PFS) at 24 months [ Time Frame: 4 years ]
    Time to disease progression including rate at specific landmark timepoint of 24 months.

  2. Overall Survival (OS) at 12 and 24 months [ Time Frame: 4 years ]
    OS rates at specific landmark timepoints of 12 and 24 months. OS is defined as the time from treatment initiation to the date of death due to any cause.

  3. Best Objective Response Rate (ORR) according to RECIST v1.1 [ Time Frame: 4 years ]
    To evaluate best ORR according to response evaluation criteria in solid tumours version 1.1 (RECIST v1.1). ORR is defined as PR or CR at any stage from time of treatment initiation according to RECIST v1.1.

  4. The safety and tolerability of 177Lu-DOTATATE or EBRT in combination with avelumab. [ Time Frame: 4 years ]
    Rate of treatment-related adverse events (AEs). Safety will be measured by serious adverse events (SAEs) and AEs assessed using the NCI CTCAE v5.0.

  5. Rate of treatment discontinuation due to toxicity [ Time Frame: 4 years ]
    This is defined as the proportion of patients who discontinue with treatment due to treatment-related toxicity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is 18 years of age or older and who has provided written informed consent.
  • Patient has histologically confirmed metastatic MCC.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 .
  • Willing and able to comply with all study protocol requirements for the duration of the study.
  • Patient must have measurable disease by CT or MRI per RECIST version 1.1 criteria.
  • Patient is treatment naïve (no prior systemic therapy for unresectable or metastatic MCC). Note that prior chemotherapy is permitted in the adjuvant setting for loco-regional disease. Prior radiation is permitted for treatment of the primary or loco-regional disease.
  • At least 2 weeks since the completion of prior therapy, including surgery or radiotherapy.
  • Screening laboratory values, obtained within 14 days prior to registration/randomisation must meet the criteria specified in the protocol.
  • Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception
  • WOCBP must have a negative serum or urine pregnancy test within within 7 days prior to the start of avelumab treatment and should be performed every 4 weeks in line with other safety bloods or clinical reviews.
  • Male patients who are sexually active with a WOCBP must use any contraceptive method with a failure rate of less than 1% per year.
  • Patient must be agreeable to have archival tumour material collected

Exclusion Criteria:

  • Patient is excluded if they have ever had any brain or leptomeningeal metastases.
  • Prior exposure to immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1/PD-L1/PD-L2, etc.) or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
  • Prior exposure to 177Lu-DOTATATE.
  • Prior malignancy within the previous 2 years, except for locally curable cancers that have been apparently cured (e.g. basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, colon, bladder or breast).
  • Life expectancy of 6 months or less.
  • An active, known or suspected autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
  • Current use of immunosuppressive medication, with exceptions detailed in the protocol
  • Prior organ transplantation, including allogeneic stem-cell transplantation.
  • Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
  • Positive test for hepatitis B virus (HBV) surface antigen and/or confirmatory hepatitis C virus (HCV) RNA (if anti-HCV antibody tested positive at Screening).
  • Pregnant or breastfeeding.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.
  • Persisting toxicity related to prior therapy (NCI CTCAE v5.0 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on Investigator's judgement are acceptable.
  • Known prior severe hypersensitivity to investigational product or any component in its formulations, including known hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5.0 Grade 3).
  • Patients with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable.
  • Use of any live vaccines against infectious diseases (e.g., influenza, varicella, etc.) within 30 days of registration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04261855

Layout table for location contacts
Contact: Melanoma and Skin Cancer Trials Coordinator +61 3 9903 9022 gotham@masc.org.au

Layout table for location information
Australia, New South Wales
Royal North Shore Hospital Recruiting
Sydney, New South Wales, Australia, 2065
Contact: A/Prof Alexander Guminski    0299265020    Alexander.Guminski@health.nsw.gov.au   
Principal Investigator: A/Prof Alexander Guminski         
Australia, Queensland
Royal Brisbane and Women's Hospital Recruiting
Brisbane, Queensland, Australia, 4029
Contact: A/Prof David Wyld    0726468111    David.wyld@health.qld.gov.au   
Principal Investigator: Prof David Wyld         
Sub-Investigator: A/Prof David Pattison         
Sub-Investigator: A/Prof Melissa Eastgate         
Princess Alexandra Hospital Recruiting
Brisbane, Queensland, Australia, 4102
Contact: Wen Xu    07 3176 2111    Wen.Xu@health.qld.gov.au   
Principal Investigator: Dr Wen Xu         
Australia, South Australia
Royal Adelaide Hospital Recruiting
Adelaide, South Australia, Australia, 5000
Contact: Prof Michael Brown    0734438049    MichaelP.Brown@sa.gov.au   
Principal Investigator: Prof Michael Brown         
Australia, Victoria
Peter MacCallum Cancer Centre Recruiting
Melbourne, Victoria, Australia, 3000
Contact: Dr Lavinia Spain    0385595000    lavinia.spain@petermac.org   
Principal Investigator: Dr Lavinia Spain         
Australia, Western Australia
Sir Charles Gaidner Hospital Recruiting
Perth, Western Australia, Australia, 6009
Contact: Dr Tarek Meniawy    0864573333    Tarek.Meniawy@health.wa.gov.au   
Principal Investigator: Dr Tarek Meniawy         
Sponsors and Collaborators
Melanoma and Skin Cancer Trials Limited
Layout table for investigator information
Study Chair: Shahneen Sandhu, MBBS, FRACP Peter MacCallum Cancer Centre, Australia
Layout table for additonal information
Responsible Party: Melanoma and Skin Cancer Trials Limited
ClinicalTrials.gov Identifier: NCT04261855    
Other Study ID Numbers: 10.17
First Posted: February 10, 2020    Key Record Dates
Last Update Posted: February 15, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Melanoma and Skin Cancer Trials Limited:
peptide receptor radionuclide therapy
neuroendocrine tumour
rare cancer
merkel cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Merkel Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Polyomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Carcinoma, Neuroendocrine
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Lutetium Lu 177 dotatate
Antineoplastic Agents, Immunological
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action